2019 China Automated Microbiology Market – Emerging Assays, Sales Forecasts and Profiles of Leading Industry Players

DUBLIN–(BUSINESS WIRE)–The “China Automated Microbiology Market for over 100 Tests” report has been added to ResearchAndMarkets.com’s offering. This report examines current and emerging assays; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay and application; profiles leading players and potential market entrants; and suggests alternative market penetration strategies for suppliers. The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbi...

Brain cancer remains challenging to diagnose, due to nonspecific symptoms and a lack of cost-effective tests.

Brain cancer remains challenging to diagnose, due to nonspecific symptoms and a lack of cost-effective tests. A new blood test that uses attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy in conjunction with machine learning technology, may help advance the detection of brain cancer. The patented technology, developed by a team at the University of Strathclyde, uses infrared light to produce a “bio-signature” of a blood sample and applies artificial intelligence to check for the signs of cancer. The research is published in Nature Communications in a paper titled, “Development of high-throughput ATR-FTIR technology for rapid triage of brain cancer.” In the paper, the researchers describe the development of instrumentation for the analysis of serum that is able to differentiate cancer and control patients at a sensitivity and specificity of 93.2% and 92.8%. In addition, preliminary data from the first prospective clinical validation study are presented. This research is advancing towards clinical translation and is being commercialized by ClinSpec Diagnostics. “This is the first publication of data from our clinical feasibility study and it is the f...